Faculty Collaboration Database

What determines who develops graft-versus-host disease: the graft or the host (or both)? Bone Marrow Transplant 1992 Aug;10(2):99-102

Date

08/01/1992

Pubmed ID

1525613

Scopus ID

2-s2.0-0026699425 (requires institutional sign-in at Scopus site)   7 Citations

Abstract

Considerable experimental data suggest that most, if not all, recipients of conventional (non-T cell-depleted) HLA-identical sibling transplants are likely to develop graft-versus-host disease (GVHD). This is because all donor-recipient pairs are likely to be disparate for numerous non-HLA antigens and because these grafts contain substantial numbers of donor T cells. However, about one-third to one-half of recipients of this type of transplant have little or no GVHD. Here we review recent data in humans suggesting that others factors, like the ability of the host to modulate GVHD reactivity of immune competent cells in the graft, may explain lack of GVHD in some persons. This concept may have implications for preventing and treating GVHD in humans.

Author List

Gale RP, Horowitz MM, Butturini A, Barrett AJ, Kolb HJ

Author

Mary M. Horowitz MD, MS Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Animals
Bone Marrow Transplantation
Dogs
Graft vs Host Disease
HLA Antigens
Histocompatibility Antigens Class II
Host vs Graft Reaction
Humans
Mice
T-Lymphocytes